Bumetanide As a Candidate Treatment for Behavioral Problems in Tuberous Sclerosis Complex

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Tuberous sclerosis complex (TSC) is associated with excitatory GABAergic neurotransmission.
• This excitatory action may underlie recurrent seizures and behavioral issues in TSC patients.
• Enhancing GABAergic transmission via chloride regulation is a potential therapeutic strategy.

Observation:

• A female adolescent with TSC and refractory seizures, sensory hyper-reactivity, and compulsive behaviors was treated with bumetanide.
• Bumetanide, a chloride transporter antagonist, was administered to assess its effects.
• Evaluation included behavioral questionnaires, event-related potentials (ERP), and resting-state EEG.

Findings:

• Six months of bumetanide treatment led to significant behavioral improvements, confirmed by parent questionnaires.
• Resting-state EEG and ERP data indicated reduced hyperexcitability.
• Bumetanide positively impacted sensory processing in the patient.

Implications:

• These findings support further investigation of bumetanide for neuropsychiatric outcomes in TSC.
• Targeting chloride regulation may offer a novel approach to managing TSC-related symptoms.
• Bumetanide shows potential as an adjunctive therapy for complex neurological and behavioral conditions.